BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer R, Watts C, McAbee J, Angelopoulos N, Gorlia T, Golfinopoulos V, Kros JM, Verhaak RGW, Bours V, van den Bent MJ, McDermott U, Robe PA, French PJ. Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. J Clin Oncol 2020;38:81-99. [PMID: 31743054 DOI: 10.1200/JCO.19.00367] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Huo C, Yin J, Tian L, Ma L, Wang D. Hypermethylation of the Promoter of miR-338-5p Mediates Aberrant Expression of ETS-1 and Is Correlated With Disease Severity Of Astrocytoma Patients. Front Oncol 2021;11:773644. [PMID: 34858853 DOI: 10.3389/fonc.2021.773644] [Reference Citation Analysis]
2 Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, Wong ET, Gerstner ER, Dietrich J, Plotkin SR, Norden AD, Lee EQ, Nayak L, Tanaka S, Wakimoto H, Lelic N, Koerner MV, Klofas LK, Bertalan MS, Arrillaga-Romany IC, Betensky RA, Curry WT, Borger DR, Balaj L, Kitchen RR, Chakrabortty SK, Valentino MD, Skog J, Breakefield XO, Iafrate AJ, Batchelor TT. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol 2020;4:PO. [PMID: 32923886 DOI: 10.1200/PO.19.00295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Golebiewska A, Hau AC, Oudin A, Stieber D, Yabo YA, Baus V, Barthelemy V, Klein E, Bougnaud S, Keunen O, Wantz M, Michelucci A, Neirinckx V, Muller A, Kaoma T, Nazarov PV, Azuaje F, De Falco A, Flies B, Richart L, Poovathingal S, Arns T, Grzyb K, Mock A, Herold-Mende C, Steino A, Brown D, May P, Miletic H, Malta TM, Noushmehr H, Kwon YJ, Jahn W, Klink B, Tanner G, Stead LF, Mittelbronn M, Skupin A, Hertel F, Bjerkvig R, Niclou SP. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathol 2020;140:919-49. [PMID: 33009951 DOI: 10.1007/s00401-020-02226-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
4 Johnson RM, Phillips HS, Bais C, Brennan CW, Cloughesy TF, Daemen A, Herrlinger U, Jenkins RB, Lai A, Mancao C, Weller M, Wick W, Bourgon R, Garcia J. Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. Neuro Oncol 2020;22:1742-56. [PMID: 32897363 DOI: 10.1093/neuonc/noaa157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Zreik J, Moinuddin FM, Yolcu YU, Alvi MA, Chaichana KL, Quinones-hinojosa A, Bydon M. Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the national cancer database from 2004 to 2013. J Neurooncol 2020;148:69-79. [DOI: 10.1007/s11060-020-03469-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
6 Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, Simonelli M, Michiara M, Caccese M, Anghileri E, Cerretti G, Rudà R, Zagonel V, Lombardi G. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). Cancers (Basel) 2021;13:2773. [PMID: 34204877 DOI: 10.3390/cancers13112773] [Reference Citation Analysis]
7 Brognaro E. The inverse paradigm and the ancestral cell of IDH-wildtype glioblastoma. Clin Transl Oncol 2021. [PMID: 34152549 DOI: 10.1007/s12094-021-02663-0] [Reference Citation Analysis]
8 Khater AR, Abou-Antoun T. Mesenchymal Epithelial Transition Factor Signaling in Pediatric Nervous System Tumors: Implications for Malignancy and Cancer Stem Cell Enrichment. Front Cell Dev Biol 2021;9:654103. [PMID: 34055785 DOI: 10.3389/fcell.2021.654103] [Reference Citation Analysis]
9 Hsu JB, Lee TY, Cheng SJ, Lee GA, Chen YC, Le NQK, Huang SW, Kuo DP, Li YT, Chang TH, Chen CY. Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response. J Pers Med 2021;11:1047. [PMID: 34834399 DOI: 10.3390/jpm11111047] [Reference Citation Analysis]
10 Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 2020;22:1073-113. [PMID: 32328653 DOI: 10.1093/neuonc/noaa106] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 79.0] [Reference Citation Analysis]
11 Ghiaseddin A, Hoang Minh LB, Janiszewska M, Shin D, Wick W, Mitchell DA, Wen PY, Grossman SA. Adult precision medicine: learning from the past to enhance the future. Neurooncol Adv 2021;3:vdaa145. [PMID: 33543142 DOI: 10.1093/noajnl/vdaa145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Birzu C, French P, Caccese M, Cerretti G, Idbaih A, Zagonel V, Lombardi G. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. Cancers (Basel) 2020;13:E47. [PMID: 33375286 DOI: 10.3390/cancers13010047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
13 Vils A, Bogowicz M, Tanadini-Lang S, Vuong D, Saltybaeva N, Kraft J, Wirsching HG, Gramatzki D, Wick W, Rushing E, Reifenberger G, Guckenberger M, Weller M, Andratschke N. Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. Front Oncol 2021;11:636672. [PMID: 33937035 DOI: 10.3389/fonc.2021.636672] [Reference Citation Analysis]
14 Gramatzki D, Felsberg J, Roth P, Kaulich K, von Deimling A, Rushing EJ, Reifenberger G, Weller M. The molecular evolution of glioblastoma treated by gross total resection alone. Neuro Oncol 2021;23:334-6. [PMID: 33173940 DOI: 10.1093/neuonc/noaa261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Blomquist MR, Ensign SF, D'Angelo F, Phillips JJ, Ceccarelli M, Peng S, Halperin RF, Caruso FP, Garofano L, Byron SA, Liang WS, Craig DW, Carpten JD, Prados MD, Trent JM, Berens ME, Iavarone A, Dhruv H, Tran NL. Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression. Neurooncol Adv 2020;2:vdaa078. [PMID: 32743548 DOI: 10.1093/noajnl/vdaa078] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Chai R, Li G, Liu Y, Zhang K, Zhao Z, Wu F, Chang Y, Pang B, Li J, Li Y, Jiang T, Wang Y. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med 2021;18:272-82. [PMID: 33628600 DOI: 10.20892/j.issn.2095-3941.2020.0179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Hoogstrate Y, Vallentgoed W, Kros JM, de Heer I, de Wit M, Eoli M, Sepulveda JM, Walenkamp AME, Frenel JS, Franceschi E, Clement PM, Weller M, van Royen ME, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, Golfinopoulos V, van den Bent M, French PJ. EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. Neurooncol Adv 2020;2:vdz051. [PMID: 32642719 DOI: 10.1093/noajnl/vdz051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Marker DF, Agnihotri S, Amankulor N, Murdoch GH, Pearce TM. The dominant TP53 hotspot mutation in IDH -mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications. Neurooncol Adv 2022;4:vdab182. [PMID: 35047821 DOI: 10.1093/noajnl/vdab182] [Reference Citation Analysis]
19 Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro Oncol 2020;22:601-12. [PMID: 31974566 DOI: 10.1093/neuonc/noaa015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 van de Geer WS, Hoogstrate Y, Draaisma K, Robe PA, Bins S, Mathijssen RHJ, French P, van de Werken HJG, de Vos FYF. Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas. Neurooncol Adv 2022;4:vdab177. [PMID: 35047820 DOI: 10.1093/noajnl/vdab177] [Reference Citation Analysis]
21 Lombardi G, Idbaih A, Le Rhun E, Preusser M, Zagonel V, French P. A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma? Cancers (Basel) 2020;12:E3775. [PMID: 33333830 DOI: 10.3390/cancers12123775] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Tesileanu CMS, van den Bent MJ, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Sabedot TS, Hoogstrate Y, von Deimling A, de Heer I, van IJcken WFJ, Brouwer RWW, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, Noushmehr H, French PJ. Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro Oncol 2021:noab088. [PMID: 33914057 DOI: 10.1093/neuonc/noab088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Weenink B, French PJ, Sillevis Smitt PAE, Debets R, Geurts M. Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. Cancers (Basel) 2020;12:E751. [PMID: 32235752 DOI: 10.3390/cancers12030751] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
24 Verduin M, Primakov S, Compter I, Woodruff HC, van Kuijk SMJ, Ramaekers BLT, te Dorsthorst M, Revenich EGM, ter Laan M, Pegge SAH, Meijer FJA, Beckervordersandforth J, Speel EJ, Kusters B, de Leng WWJ, Anten MM, Broen MPG, Ackermans L, Schijns OEMG, Teernstra O, Hovinga K, Vooijs MA, Tjan-Heijnen VCG, Eekers DBP, Postma AA, Lambin P, Hoeben A. Prognostic and Predictive Value of Integrated Qualitative and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma. Cancers (Basel) 2021;13:722. [PMID: 33578746 DOI: 10.3390/cancers13040722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Dekker LJM, Kannegieter NM, Haerkens F, Toth E, Kros JM, Steenhoff Hov DA, Fillebeen J, Verschuren L, Leenstra S, Ressa A, Luider TM. Multiomics profiling of paired primary and recurrent glioblastoma patient tissues. Neurooncol Adv 2020;2:vdaa083. [PMID: 32793885 DOI: 10.1093/noajnl/vdaa083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Chen Y, Jin Y, Wu N. Role of Tumor-Derived Extracellular Vesicles in Glioblastoma. Cells 2021;10:512. [PMID: 33670924 DOI: 10.3390/cells10030512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 El-Khayat SM, Arafat WO. Therapeutic strategies of recurrent glioblastoma and its molecular pathways 'Lock up the beast'. Ecancermedicalscience 2021;15:1176. [PMID: 33680090 DOI: 10.3332/ecancer.2021.1176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Luan XZ, Wang HR, Xiang W, Li SJ, He H, Chen LG, Wang JM, Zhou J. Extracranial multiorgan metastasis from primary glioblastoma: A case report. World J Clin Cases 2021; 9(33): 10300-10307 [PMID: 34904103 DOI: 10.12998/wjcc.v9.i33.10300] [Reference Citation Analysis]